04/11/2025 09:24

ResMed Inc (RMD) $37.83

RMD retreated 4.3% on Monday, its largest decline since April, after the sleep apnoea business reported 1Q results. The main issue was that organic growth slowed, marking the 3rd consecutive quarter of slowing organic growth rates.

Read more

29/10/2025 09:39

ResMed Inc (RMD) $39.29

RMD remains a global leader in sleep and respiratory care, offering CPAP devices, masks, and digital health software that treat sleep apnoea and chronic respiratory disorders.

Read more

16/09/2025 09:43

ResMed Inc (RMD) $40.68

RMD has drifted 10% in recent weeks, taking its direction from a lacklustre healthcare sector. The stock rallied into and through its fourth quarter FY25 earnings on July 31st but its struggled since, taking little solace from a strong market.

Read more

07/03/2025 09:22

ResMed Inc (RMD) $35.65

Sleep disorder business RMD fell 3.4% on Thursday, making it the standout loser in the healthcare sector after founder Peter Farrell sold $500k worth of shares.

Read more

13/02/2025 09:28

ResMed Inc (RMD) $37.55

Sleep disorder business RMD has slipped from all-time highs after reporting its quarterly results last week. The weakening trend in organic sales overshadowed the strong financial performance. This remains an impressive business, but after recovering strongly from Ozempic worries in 2024, we must consider what is next.

Read more

03/02/2025 17:14

ResMed (RMD) $38.94

RMD -3.09%: Reported quarterly results in the US on Friday that were solid on first pass, though the market has latched onto a weaking trend from organic sales which overshadowed the strong financial performance.

Read more

09/08/2024 09:27

ResMed Inc (RMD) $32.52

Sleep apnoea company RMD has experienced a wild ride over the last year as news from weight loss companies has impacted its share price week to week more than specific news about the company itself. Earlier this month, RMD delivered a largely in-line 4Q, with revenue and core EPS both close to consensus. Revenue growth was 9% y/y and core EPS showed 30% growth y/y.

Read more

30/07/2024 09:27

ResMed Inc (RMD) v Dexcom (DXCM US)

RMD fell over 2% on Monday following an update from Nasdaq-listed Dexcom (DXCM US). The US-listed stock plunged over 40%, its largest drop in history, after they reported disappointing revenue and lowered its full-year guidance. Dexcom offers a suite of tools, such as continuous glucose monitors, for patients who have been diagnosed with diabetes.

Read more

26/04/2024 09:17

ResMed Inc (RMD US) $US183.42

ResMed reported after the US market closed this morning with Q3 adjusted EPS of $2.13 ahead of the consensus of $1.91, a result that’s likely to be welcomed locally this morning, with the stock up ~5% in late trade. Earnings were helped by revenue of $1.2bn, which was 7.2% ahead of consensus; its quarterly dividend was maintained at 48c. Today's price action will be interesting as MM is not keen on stocks that cannot rally on “good news.”

Read more

17/04/2024 09:35

ResMed (RMD) versus CSL Ltd (CSL)

The Australian Healthcare is trading at a ~70% premium to the ASX 200 on a 1-year forward PE, which is close to its recent normal; hence, we are considering switching with the sector as opposed to outright buying or selling. RMD & CSL are two very different healthcare businesses, although both suffered in 2023 at the hands of Ozempic et al.. In both cases, the sell-off was over-blown in our opinion, but that’s the nature of stocks when the crowd runs as one.

Read more